Related Experiment Video
Updated: Aug 11, 2026
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Using multiple drug exposure levels to optimize power in pharmacogenetic trials
1Genaissance Pharmaceuticals, 5 Science Park, New Haven, CT 06511, USA.
Journal of Clinical Pharmacology
|September 5, 2003
Summary
Future large-scale pharmacogenetic trials require optimal design. Drug exposure levels significantly impact the power to detect genetic associations with drug response, suggesting multi-dose trials enhance discovery.
Area of Science:
- Pharmacogenetics
- Clinical Trial Design
- Genomics
Background:
- Decreasing genotyping costs enable large-scale pharmacogenetic trials examining numerous single-nucleotide polymorphisms (SNPs).
- Designing these extensive trials presents a significant challenge for researchers.
- Understanding the influence of drug exposure on detecting genetic associations is crucial.
Purpose of the Study:
- To demonstrate how drug exposure levels affect the statistical power in pharmacogenetic studies.
- To develop and analyze a model simulating pharmacogenetic trials to explore exposure-sensitivity relationships.
- To evaluate the impact of different clinical trial designs on identifying pharmacogenetic associations.
Main Methods:
- Development of an analytical model for drug response.
- Simulation of pharmacogenetic trials using the developed model.
- Conducting analytical and numerical sensitivity analyses to assess exposure-response relationships.
- Investigating two distinct clinical trial designs.
Main Results:
- The power to detect pharmacogenetic associations can be a nonlinear and nonmonotonic function of drug exposure.
- Drug exposure level is a critical factor influencing the ability to find true genetic associations.
- Simulations revealed complex interactions between genetic polymorphisms, drug response, and exposure levels.
Conclusions:
- Optimal pharmacogenetic trial design must account for the variable effects of drug exposure.
- Clinical trial designs incorporating multiple drug exposures or doses increase the likelihood of discovering significant pharmacogenetic associations.
- These findings are vital for optimizing future large-scale genetic association studies in drug response.
More Related Videos
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...